A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers

Yang Han, Su Lu, Fudong Yu, Xisheng Liu, Huimin Sun, Jingtao Wang, Xingwu Zhu, Huijun Lu, Hao Yue, Jun Lin, Chongzhi Zhou, Huamei Tang, Zhihai PengScientific 2016 · DOI

Abstract

Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analyzed the outcomes of 902 patients with colorectal cancer treated with or without chemotherapy in our hospital. We found Chinese survival benefit for chemotherapy was consistent with current guidelines. Moreover, our data added to the evidence that chemotherapy might be used for elderly patients with stage II high-risk colorectal cancer. Pathological markers could predict response to individualize therapy in a convenient, fast and inexpensive way. We compared survivals of patients with stage II high-risk and stage III colorectal cancer with chemotherapy in different pathological markers expression, and furthermore used 458 colon adenocarcinoma samples from The Cancer Genome Atlas to verify our preliminary results. We confirmed TOPIIα, EGFR and P170 may be sufficiently predictive markers to individualize chemotherapy. FOLFOX was the optimal adjuvant chemotherapy for patients with stage II high-risk and stage III colorectal cancer when TOPIIα was positive or EGFR or P170 was negative.

Introduction

Colorectal cancer (CRC) remains a significant global health challenge. While adjuvant chemotherapy (AC) following surgery is the standard of care for stage III and high-risk stage II patients, the "one-size-fits-all" approach often leads to unnecessary toxicity without guaranteed survival benefits. Current clinical guidelines lack the precision needed to tailor treatments to individual patients. This study explores the use of routine pathological markers as a cost-effective and accessible means to guide individualized chemotherapy.

Methods and Datasets

The study utilized a dual-cohort approach to identify and validate predictive markers:

  1. Hospital Cohort: 902 patients from Shanghai General Hospital (2003–2010) underwent Immunohistochemistry (IHC) to evaluate 14 routine pathological markers.
  2. Validation Cohort: 448 colon adenocarcinoma samples from The Cancer Genome Atlas (TCGA) were analyzed at the mRNA level using HiSeq sequencing to verify the preliminary findings.
Study workflow for identifying and validating pathological markers in CRC cohorts.

Researchers employed Cox proportional hazards models to determine prognostic factors and Kaplan-Meier curves to compare Overall Survival (OS) and Disease-Free Survival (DFS) across various chemotherapy regimens, including FOLFOX, CapeOX, 5-Fu/LV, and capecitabine.

Key Insights: The Predictive Trio

The analysis identified three routine markers—TOPIIα (Topoisomerase IIα), EGFR (Epidermal Growth Factor Receptor), and P170 (P-glycoprotein)—as highly predictive of chemotherapy response.

The study established a "winning formula" for treatment: the FOLFOX regimen provided the most significant survival benefit when TOPIIα was positive or when EGFR or P170 were negative. Furthermore, the predictive power was synergistic; patients exhibiting the favorable profile (EGFR-, TOPIIα+, and P170-) showed the most marked improvement in outcomes with FOLFOX.

Key Results

The findings underscore the efficacy of individualized adjuvant chemotherapy:

  • Overall Survival: Patients receiving chemotherapy achieved a 5-year OS of 81.1%, significantly outperforming those who did not.
  • Regimen Efficacy: For stage III and high-risk stage II patients, combination therapies like FOLFOX and CapeOX were superior to single-agent regimens. In the high-risk stage II group, these combinations reached a 90% 5-year survival rate.
  • Elderly Patients: The data suggests that high-risk stage II patients over 75 years old can still benefit significantly from individualized chemotherapy, challenging some existing clinical hesitations.
Kaplan-Meier survival analysis comparing different chemotherapy regimens across AJCC stage II and III subgroups.

Conclusion and Limitations

This research provides a practical framework for precision oncology using inexpensive, routine pathology. While the retrospective nature of the study and the differences between protein (IHC) and mRNA (TCGA) expression levels are noted limitations, the consistency of the results across cohorts is promising. Future multi-center prospective randomized controlled trials are necessary to formally integrate these markers into standard clinical practice.

Summary updated

Abstract

Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analyzed the outcomes of 902 patients with colorectal cancer treated with or without chemotherapy in our hospital. We found Chinese survival benefit for chemotherapy was consistent with current guidelines. Moreover, our data added to the evidence that chemotherapy might be used for elderly patients with stage II high-risk colorectal cancer. Pathological markers could predict response to individualize therapy in a convenient, fast and inexpensive way. We compared survivals of patients with stage II high-risk and stage III colorectal cancer with chemotherapy in different pathological markers expression, and furthermore used 458 colon adenocarcinoma samples from The Cancer Genome Atlas to verify our preliminary results. We confirmed TOPIIα, EGFR and P170 may be sufficiently predictive markers to individualize chemotherapy. FOLFOX was the optimal adjuvant chemotherapy for patients with stage II high-risk and stage III colorectal cancer when TOPIIα was positive or EGFR or P170 was negative.
BibTeX
@inproceedings{han2016comparative,
  author = {Yang Han and Su Lu and Fudong Yu and Xisheng Liu and Huimin Sun and Jingtao Wang and Xingwu Zhu and Huijun Lu and Hao Yue and Jing Wang and Jun Lin and Chongzhi Zhou and Huamei Tang and Zhihai Peng},
  title = {{A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers}},
  booktitle = {Scientific},
  year = {2016},
  doi = {10.1038/srep37240},
}
Figure